

# Curriculum Vitae

**Full Name: Mitsumasa Kishimoto, MD, PhD**

**Organization: Immuno-Rheumatology Center, St Luke`s International University and Hospital.**

**Position & Title: Clinical Program Director**

**Educational background & professional experience**

## WORK POSITION

- Aug 2009 – present: Immuno-Rheumatology Center, St. Luke`s international hospital  
 Aug 2006 – Jul 2009: Chief, Department of Rheumatology, Kameda Medical Center  
 Apr 2015– present: Clinical professor, Tokyo Medical and Dental University  
 Apr 2007 – present: Adjunct assistant professor, Faculty of Medicine, the University of Tokyo  
 Nov 2014 – present ASAS member  
 Nov 2014 – present GRAPPA member

## POST-GRADUATE TRAINING

- Jul 2004 – Jun 2006 Rheumatology Fellowship at New York University, Hospital for Joint Diseases  
 Jun 2001 – Jun 2004 University of Hawaii Internal Medicine Residency Program Honolulu, Hawaii  
 Apr 2000 – Apr 2001 Rotating Intern, Japanese National Physician Graduate Medical Education Program, U.S. Naval Hospital, Okinawa, Japan  
 May 1998 – April 2000 Postgraduate Medical Education Program, Okinawa Chubu Hospital, Okinawa, Japan

## Research Interests

- Dec 2016-present Principal investigator in Japan, "ASAS-PerSpA", multicenter studies lead by ASAS (Dr Maxime Dougados)  
 Apr 2018-present Steering committee member, "Japan College of Rheumatology recommendation for management of rheumatoid arthritis update" supported by the Japanese Ministry of Health, Labor and Welfare  
 Sep 2018-present Steering committee member, "APLAR guideline for management of spondyloarthritis" supported by the

Apr 2014- present	APLAR Committee member, "Epidemiology assessment for Psoriasis and psoriatic arthritis in Japan" supported by the Japanese Ministry of Health, Labor and Welfare
Apr 2013-Mar 2018	Steering committee member, "APLAR guideline for management of rheumatoid arthritis" supported by the APLAR
Dec 2012-present	Principal investigator in Japan, "ASAS-COMOSPA", multicenter studies lead by ASAS (Dr Maxime Dougados)

## Publications (Max: 5 titles / in sequence of the latest year)

1. **Kishimoto M**, Taniguchi A, Fujishige A, Kaneko S, Haemmerle S, Porter BO, Kobayashi S. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J). *Mod Rheumatol*. 2019 Jan 3:1-9. doi: 10.1080/14397595.2018.1538004. [Epub ahead of print]
2. Tam LS, Wei JCC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, **Kishimoto M**, Reyes HM, Soroosh S, Stebbings S, Whittle S, Yeap SS, Lau CS. 2017 APLAR axial spondyloarthritis treatment recommendations. *Int J Rheum Dis* 2019;22(3):340-356
3. Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, **Kishimoto M**, Kumar A, Leong KP, Li Z, Lichauco JJ, Louthrenoo W, Luo SF, Mu R, Nash P, Ng CT, Suryana B, Wijaya LK, Yeap SS. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. *Int J Rheum Dis*. 2019 Mar;22(3):357-375.
4. **Kishimoto M**, Yoshida K, Ichikawa N, Inoue H, Kaneko Y, Kawasaki T, Matsui K, Morita M, Suda M, Tada K, Takizawa N, Tamura N, Taniguchi A, Taniguchi Y, Tsuji S, Haji Y, Rokutanda R, Yanaoka H, Cheung PP, Gu J, Kim TH, Luo SF, Okada M, Medina CL, Molto A, Dougados M, Kobayashi S, van der Heijde D, Tomita T. Clinical characteristics of spondyloarthritis patients in Japan in comparison to other regions of the world. *J Rheumatol* 2019 Feb 15. [Epub ahead of print]
5. Gottlieb AB, Strand V, **Kishimoto M**, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). *Rheumatology* 2018;57(10):1777-1788.